The Biden administration expects to take a delivery of 4 million courses of COVID-19 treatments by the end of January, including 265,000 courses of Pfizer Inc.’s newly authorized pill, according to officials familiar with the matter — sharply ramping up therapies for the disease as the omicron variant spreads.
Pfizer’s pill was authorized Wednesday by the Food and Drug Administration, and authorization for Merck & Co.’s pill was also expected this week.
The overall group of treatments includes a monoclonal antibody product, pre-exposure preventive drugs for immunocompromised people, and new antiviral pills, the officials said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.